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The development of a novel tuberculosis vaccine is a leading global health priority. SRL172,
an inactivated, whole-cell mycobacterial vaccine, was safe, immunogenic and reduced the
incidence of culture-confirmed tuberculosis in a phase III trial in HIV-infected and BCG
immunized adults in Tanzania. Here we describe the immunogenicity and protective efficacy
of DAR-901, a booster vaccine against tuberculosis manufactured from the same seed
strain using a new scalable method.
Methods
We evaluated IFN-γ responses by ELISpot and antibody responses by enzyme linked
immunosorbent assay in C57BL/6 and BALB/c mice after three doses of DAR-901. In an
aerosol challenge model, we evaluated the protective efficacy of the DAR-901 booster in
C57BL/6 mice primed with BCG and boosted with two doses of DAR-901 at 4 dosage levels
in comparison with homologous BCG boost.
Results
DAR-901 vaccination elicited IFN-γ responses to mycobacterial antigen preparations
derived from both DAR-901 and Mycobacterium tuberculosis. DAR-901 immunization
enhanced antibody responses to DAR-901 but not Mycobacterium tuberculosis lysate or
purified protein derivative. Among animals primed with BCG, boosting with DAR-901 at 1
mg provided greater protection against aerosol challenge than a homologous BCG boost
(lungs P = 0.036, spleen P = 0.028).
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Conclusions
DAR-901 induces cellular and humoral immunity and boosts protection from M. tuberculosis
compared to a homologous BCG boost.
Introduction
Tuberculosis sickens over eight million people and kills more than one million every year [1,
2]. The standard vaccine against tuberculosis, Mycobacterium bovis, bacille Calmette-Guerin
(BCG), is effective when administered to mycobacteria-naïve infants, but protection appears
to wane after 10–15 years [3] and boosting with another administration of BCG is ineffective
[4, 5] The development of improved vaccines against tuberculosis is thus a critical global health
priority [6]. Modeling studies indicate that an effective BCG booster for adolescents and adults
will have a greater impact on the global pandemic than an improved BCG for priming infants
[7].
Our work has focused on development of a booster vaccine for BCG. We have shown previ-
ously that a multiple-dose series of SRL172, an inactivated, whole-cell vaccine prepared from a
non-tuberculous mycobacterium was safe, well-tolerated and immunogenic in humans [8–
10]. A randomized controlled Phase III trial in Tanzania demonstrated that boosting with
SRL172 protected against culture-confirmed tuberculosis in HIV-infected adults who had
received BCG at birth [11].
DAR-901, a vaccine produced from the same seed strain using a new, scalable manufactur-
ing method, has entered clinical development. In this report, we present the results of preclini-
cal studies of the immunogenicity and protective efficacy of DAR-901 in mice.
Methods
Fig 1 depicts a schedule of study visits and assessments.
Mice
Immunogenicity Experiments. We obtained female 8–10 week old C57BL/6 and BALB/c
mice from Jackson Laboratory (Bar Harbor, Maine) and maintained them in pathogen-free
conditions. Animal experiments were reviewed and approved by the Noble Life Sciences Insti-
tutional Animal Care and Use Committee (IACUC). We conducted experiments according to
guidelines set out by the Association for Assessment and Accreditation of Laboratory Animal
Care International (AAALAC). Prior to vaccine administration at weeks 0, 2 and 4, mice were
anesthetized using tribromoethanol 250mg/kg intraperitoneally. Immunogenicity assessments
were performed in mice sacrificed by carbon dioxide asphyxiation at weeks 2, 4 and 6. Animals
were monitored continuously throughout experimental procedures, routinely following any
procedures (e.g., to ensure full recovery from anesthesia), and otherwise on a daily basis. No
procedures involved in this study caused more than momentary pain/distress (e.g., subcutane-
ous immunizations). Our IACUC protocol allows the vivarium to euthanize any animals that
appear to be in any pain or distress. No animals died prior to the experimental endpoint; there
were no observations of significant pain/distress.
Challenge experiments. We obtained specific pathogen-free, female 6–9 weeks old
C57BL/6 mice from Charles River (United Kingdom). All animal procedures were approved
by the National Institute for Biological Standards and Control ethics committee and were in
accordance with UK Home Office (Scientific Procedures) Act 1986. Mice were primed with
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BCG at week zero, boosted with the indicated immunization at weeks 12 and 14, challenged by
exposure to Mycobacterium tuberculosis at week 20, and growth of M. tuberculosis in spleen
and lung assessed at week 23 (as below) following euthanasia by cervical dislocation. Through-
out the study, mice were monitored by trained animal technicians at least once a day. If
any adverse reactions or abnormalities were observed, the monitoring frequency could be
increased. Per protocol, mice with greater than 20% loss of body weight and mice with adverse
reactions that exceeded the “Moderate” severity grade were to be sacrificed.
Vaccine
Vaccine preparation. DAR-901 is an inactivated, whole cell mycobacterial vaccine pre-
pared from the Master Cell Bank for SRL172, which was prepared from organisms grown on
agar. DAR-901 was manufactured by Aeras (Rockville, MD) using organisms grown by broth
fermentation. SRL172 was originally identified as a Mycobacterium vaccae based on pheno-
typic characteristics [12]. 16S rRNA gene sequencing of the seed strain demonstrates >99.6%
identity to the reference 16S rRNA sequence for Mycobacterium obuense and 100% identity to
SRL172. DAR-901 is distributed in 2 mL vials containing 0.3–0.4 mL of a 1 mg/mL suspension
of heat-inactivated organisms.
Vaccination procedure. Intradermal immunizations were performed using insulin syrin-
ges (BD Biosciences, San Jose, CA). DAR-901 was diluted to various doses (0.1 to 2.5 mg/dose)
in citrate buffer and administered in a total volume of 50 μL. Vaccine was administered at
Fig 1. Schedule of study visits and assessments. In immunogenicity experiments, mice were immunized with varying doses of DAR-
901 at weeks 0, 2 and 4, and assessments of antigen-specific interferon gamma responses were undertaken at weeks 2, 4 and 6. Antibody
responses were assessed at week 2. In our challenge experiment, mice were immunized with BCG vaccine at week 0, and then boosted
with the indicated saline, BCG or DAR-901 dose levels at weeks 12 and 14. At week 20 mice were challenged with Mycobacterium
tuberculosis (MTB). For mice in challenge experiments, growth of MTB was assessed in lungs and spleen at week 32. BCG, bacille
Calmette Guerin; CFU, colony forming units; MTB, Mycobacterium tuberculosis
doi:10.1371/journal.pone.0168521.g001
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alternating sites on the stomach of anesthetized mice every two weeks up to a total of three
doses. For in vitro assays, mice were sacrificed at 2 weeks after the first, second and third
doses, blood samples were obtained and splenocytes isolated.
Immunological assays
ELISpot assay. ELISpot assays were conducted in 96-well polyvinylidene fluoride ELISpot
plates (Millipore, Billerica, MA) with R&D Systems Mouse Interferon- ELISpot kit (R&D Sys-
tem, Minneapolis, MN), as previously described [13]. Briefly, plates were coated with anti-
mouse capture antibodies and incubated overnight at 4˚C. The following day, plates were
washed with PBS and blocked for two hours with RPMI 1640 medium containing 10% fetal
bovine serum, 55 μM mercaptoethanol (Sigma, St. Louis, MO), 10 mM HEPES buffer (Gibco,
Grand Island, NY), 2 mM L-glutamine (Gibco) and 1x penicillin/streptomycin (Life Technolo-
gies) (R10). Splenocytes (2x105 cells per well, in triplicate) were incubated overnight at 37˚C
with R10 (negative control), and 0.4 μg of each antigen.
Antibody ELISA. 96-well Thermo Scientific Immuno Plates (Fisher Scientific, Pittsburgh,
PA) were coated overnight with 1 μg/well antigen at 2–8˚C, washed with 1X PBS containing
0.05% Tween-20, blocked with 1X PBS containing 5% non-fat dry milk, incubated at room
temperature for two hours with diluted mouse serum, washed, incubated at room temperature
for one hour with anti-mouse IgG-HRP (Santa Cruz Biotechnology, Dallas, TX), washed, incu-
bated in the dark at room temperature with 3,3’,5,5’-tetramethylbenzidine (TMB) substrate
(BD Biosciences), and substrate development stopped after 30 minutes. The plates were read
on a SpectraMax Plus 384 plate reader (Molecular Devices, Sunnyvale, CA). The results shown
represent the mean of duplicate wells.
Challenge study
Challenge. Groups of ten mice were primed intradermally with 1 × 105 colony forming
units (CFU) of culture grown BCG-TICE strain or with sterile saline. BCG vaccinated groups
of mice were scheduled to be boosted with either three intradermal doses of DAR-901 at vari-
ous dosage (0.1 to 2.5 mg/ dose) at week 12, 14 and 16, or a second dose of BCG at week 12.
No anesthetics or analgesics were used at the time of injection. Six weeks after the second
DAR-901 boost vaccination, five animals per group were challenged with M. tuberculosis
H37Rv strain (MTb) by the aerosol route using a Glas-Col inhalation chamber, with a target
dose of 50–100 CFU per lung per mouse. The remaining animals were sacrificed and used for
a separate study.
Infection assessment. At 12 weeks post-challenge, all mice were sacrificed and bacterial
load in lungs and spleens determined. Samples of each tissue were homogenised separately in
cold saline + 0.01% (v/v) Digitonin with glass beads (2.5–3.5 mm), using a Fast-Prep FP120
ribolyzer at speed 6 for 30 seconds, serially diluted, plated in duplicate onto Middlebrook
7H11 agar plates supplemented with 10% oleic acid-albumin-dextrose-catalase (OADC;
Difco), 0.5% glycerol, and the plates incubated at 37˚C until CFU could be counted, typically
in 2–3 weeks.
Statistical analysis
We compared interferon gamma responses and post-challenge lung and spleen CFU of MTb
between DAR-901 vaccine dose conditions vs saline and other comparator conditions using
grouped one-way ANOVA. For grouped comparisons yielding P<0.0001 we reported the
results of comparisons between individual conditions (for instance BCG plus DAR-901 1.0 mg
vs BCG alone) using student’s t tests with a p value of<0.05 as the threshold for statistical
Protective TB Vaccine Immunogenicity
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significance. In comparisons of antibody responses to mycobacterial antigens, there were only
single averaged values for each experimental condition so we compared the average antibody
concentration of all mice that received saline to the average antibody concentration measured
in all mice that received any dose of DAR-901 using a single students t test. We depicted and
analyzed data in Prism 6 (GraphPad La Jolla, CA) and STATA 12 (College Station, TX).
Results
ELISpot
At 2 weeks after a three-dose series, DAR-901 vaccination significantly enhanced IFN-γ
responses to DAR-901 sonicate (Fig 2A and 2B), and DAR-901 culture filtrate protein (Fig 2C
and 2D) compared to saline control in both C57BL/6 and BALB/c mice. In addition, DAR-901
IFN-γ responses to M. tuberculosis purified protein derivative (PPD) and lysate were signifi-
cantly enhanced by DAR-901 vaccination compared to saline (Fig 2E and 2F). In time course
experiments in recipients of the 0.03 mg dose of DAR-901, DAR-901-specific IFN-γ responses
increased from week 2 to weeks 4 and 6 in C57BL/6 and BALB/c mice (Fig 2G and 2H, respec-
tively). DAR-901 vaccination did not elicit IFN-γ responses to commercially available poten-
tially cross-reactive mycobacterial heat shock protein Hsp65 (Fig 2I and 2J, respectively).
Antibody ELISA
Compared to saline control, DAR-901 vaccination enhanced antibody responses to DAR-901
sonicate (Fig 3A and 3B) and DAR-901 culture filtrate protein in both C57BL/6 and BALB/c
mice (Fig 3C and 3D), but not to M. tuberculosis antigens (Fig 3E and 3F). Antibody responses
to mycobacterial Hsp65 were very low magnitude in all conditions but significantly greater at
some doses among DAR-901 vaccinees compared to saline controls in C57BL/6 mice but not
BALB/c mice (Fig 3G and 3H, respectively).
Challenge study
Following the second booster vaccination, all 40 DAR-901 mice showed redness and swelling
(nodule formation) at the site of injection. In 4 mice (one each receiving 0.1 mg and 2.5 mg,
and two receiving 0.3 mg DAR-901) the nodules ruptured, producing open wounds that failed
to improve within 24 h after treatment with topical antiseptic. In response to veterinary advice
and consistent with the protocol provisions and national regulations, these mice were termi-
nated and the third booster vaccination was removed from the protocol. One mouse from the
group with homologous BCG prime and boost was found at daily check approximately four
weeks after the boost to appear distressed and in poor health and was also terminated. Post-
mortem did not identify any obvious causes for the deterioration which was assessed as unre-
lated to the vaccination procedure. One mouse in the saline group was found dead approxi-
mately 4 weeks post-challenge. This animal had appeared normal on the previous day and no
signs of distress had been observed. This event was also assessed as unrelated to the vaccination
procedure.
We assessed the growth of MTb in the lungs and spleen of mice primed with BCG with or
without booster of DAR-901 or BCG (Fig 4). A single BCG vaccination conferred protection
from challenge with MTb (compared to saline, p value in lungs 0.002 and in spleen 0.013). In
both lungs and spleen DAR-901 boosting at the 1.0 mg dose resulted in a statistically signifi-
cant reduction of MTb growth compared to a homologous BCG boost. In addition, there was
a trend toward increasing protective efficacy in animals boosted with increasing doses of
DAR-901.
Protective TB Vaccine Immunogenicity
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Discussion
SRL172 is the only modern tuberculosis vaccine demonstrated to reduce culture-confirmed
tuberculosis in a phase III randomized, double-blind, placebo-controlled, clinical trial [11].
Further development of this vaccine required a more scalable manufacturing process, which
has been addressed by the manufacture of DAR-901 from the SRL172 Master Cell Bank via a
broth-based method. We now show DAR-901 is immunogenic and, when administered as a
booster vaccine for BCG primed animals, enhanced protection against an aerosol tuberculosis
challenge compared to a homologous BCG boost.
DAR-901 elicited IFN-γ and antibody responses in mice. Although the immune correlates
of vaccine protection from tuberculosis are not known, defects in IFN-γ expression are associ-
ated with enhanced susceptibility to mycobacterial infection [14, 15], and we have shown that
IFN-γ responses against multiple mycobacterial antigens predict protection from HIV-associ-
ated tuberculosis [16, 17]. However, IFN-γ (and other) cytokine responses to tuberculosis anti-
gens failed to correlate with BCG-mediated protection from tuberculosis in a large clinical trial
in South Africa [18] and a vaccine that elicited IFN-γ responses to mycobacterial antigens did
not confer protection from tuberculosis in a phase IIb human clinical trial [19]. Although
SRL172 immunization was associated with reduced laboratory-confirmed tuberculosis among
adults with HIV infection [11], and SRL172 elicited IFN-γ responses to mycobacterial antigens
[10], IFN-γ responses to mycobacterial antigens did not correlate with vaccine-mediated pro-
tection from tuberculosis. Thus the role of IFN-γ responses in vaccine-mediated immune pro-
tection from tuberculosis is unclear.
DAR-901 immunization induced antibody responses to DAR-901 sonicate and culture fil-
trate protein when comparing all dose levels to the saline control. Antibody responses to Myco-
bacterium tuberculosis antigens, by contrast, were not increased when comparing all dose
levels together. Given the elicitation of detectable cross-reactive IFN-γ responses after DAR-
901 vaccination, the absence of detectable cross-reactive antibody responses does not suggest
the absence of cross-reactive antigens although it may hint that the cross-reactive antigens
present in DAR-901 are more effective at eliciting IFN-γ responses than antibody responses.
Some human and experimental data supports a role for antibody in protection against tuber-
culosis, although cross-protective antigens were not well-defined, while other studies showed
protection may be achieved in the absence of antibody [20–23].
BCG prime followed by two doses of DAR-901 at 1.0 mg dose conferred enhanced protec-
tion from tuberculosis challenge compared to mice boosted with BCG. In studies such as this
in which immune responses or protection from tuberculosis in a small number of genetically
homogeneous animals are assessed, there is real risk of both type I and type II error. We did
Fig 2. DAR-901 vaccination elicits interferon gamma (IFN-γ) responses to multiple mycobacterial
antigens by ELISpot assay. Mice were immunized at week 0, 2 and 4 with the indicated dose of DAR-901.
At week 2, DAR-901 vaccination elicited IFN-γ responses to DAR-901 sonicate in C57BL/6 (A) and BALB/c
(B) mice, DAR-901 culture filtrate protein in C57BL/6 (C) and BALB/c (D) mice, and to Mycobacterium
tuberculosis purified protein derivative and lysate in C57BL/6 (E) and BALB/c (F) mice. In time course
experiments, IFN-γ responses to the vaccine antigens DAR-901 sonicate and DAR-901 culture filtrate protein
progressively increased from 2 to 6 weeks after additional vaccinations with DAR-901 0.3 mg in C57BL/6 (G)
and BALB/c (H) mice. DAR-901 vaccination did not enhance IFN-γ responses to Hsp65 in C57BL/6 (I) or
BALB/c (J) mice. Splenocytes from 5 mice/dose level/time point were pooled, and the bars indicate the mean
and standard deviation of triplicate repeat measurements. P values reflect the comparison of the indicated
vaccine dose to the saline control condition using a student’s t test. * P value for DAR-901 response
compared to saline <0.05. ** P value for DAR-901 response compared to saline < 0.01. ^ P value for DAR-
901 response compared to the previous visit <0.05. ^^ P value for DAR-901 response compared to the
previous visit <0.01. CFP, culture filtrate protein; MTb, Mycobacterium tuberculosis; PPD, purified protein
derivative; SFU, spot forming units
doi:10.1371/journal.pone.0168521.g002
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Fig 3. DAR-901 vaccination elicits antibody responses to multiple mycobacterial antigens by enzyme
linked immunosorbent assay. Mice were immunized at week 0, 2 and 4 with the indicated dose of DAR-901.
At week 2, DAR-901 vaccination enhanced antibody responses to DAR-901 sonicate in C57BL/6 (A) and BALB/
c (B) mice, DAR-901 culture filtrate protein in C57BL/6 (C) and BALB/c (D) mice but not to Mycobacterium
tuberculosis purified protein derivative and lysate in C57BL/6 (E) or BALB/c (F) mice. DAR-901 vaccination
enhanced antibody responses to Hsp65 in C57BL/6 (G) but not BALB/c (H) mice, although overall responses
were very low magnitude. Serum from 5 mice/dose level was pooled and assayed in duplicate and the bars
indicate the mean of two measurements. P values reflect the comparison of all DAR-901 dose levels averaged
together to the saline control condition using a student’s t test. MTb, Mycobacterium tuberculosis; NS, non-
significant; PPD, purified protein derivative
doi:10.1371/journal.pone.0168521.g003
Fig 4. DAR-901 booster vaccination at 1 mg provided greater protection against aerosol challenge with Mycobacterium tuberculosis (MTb) in
C57BL/6 mice compared to a BCG booster vaccination. Mice were primed with BCG immunization at week zero, and boosted with the indicated
immunization at weeks 12 and 14. At study week 20, 5 mice/group were challenged with approximately 15 CFU of Mtb strain H37Rv via the aerosol route.
Twelve weeks post-challenge, bacterial burdens in the lungs (A) and spleens (B) of each mouse were enumerated. Growth of MTb in both organs was
reduced by immunization with BCG both with or without boosting with DAR-901 at different dose levels. In both tissues, there was a trend toward greater
reduction of MTb growth when BCG was followed by DAR-901 up to 1.0 mg dose. Further, in both tissues, BCG-primed animals boosted with DAR-901 at the
1.0 mg dose demonstrated significantly greater suppression of MTb growth than animals given a homologous BCG boost. Each point indicates a single
mouse; bars indicate the mean value for that experimental condition. Numerical P values at the top of the figure reflect the results of a student’s t test for the
indicated comparison, and are the only comparisons between BCG +/- DAR-901 vaccine conditions that yielded P values < 0.2. * P value for DAR-901
response compared to saline <0.05. ** P value for DAR-901 response compared to saline < 0.01. BCG, bacille Calmette-Guerin
doi:10.1371/journal.pone.0168521.g004
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not correct for multiple comparisons in order to avoid type II error in these pilot studies inves-
tigating multiple different dose conditions, and believe our results are plausible in part because
they align exactly with prior mouse and human studies. Mouse and other animal models of
tuberculosis vaccine efficacy which do not exhibit the latent phase of infection–such as charac-
terizes the vast majority of human infections with Mycobacterium tuberculosis–have not yet
been able to distinguish between effective and ineffective tuberculosis vaccines in humans [24,
25]. For instance, the tuberculosis booster vaccine candidate MVAg85A protected from tuber-
culosis after parenteral and intranasal administration in animal models [26–28] but did not
protect human infants from tuberculosis when given parenterally in a prime boost trial design
[19, 29]. Thus, protective efficacy in animal models should be weighed along with other impor-
tant considerations when advancing a candidate into clinical development.
Our data build on previous studies showing that heat inactivated whole mycobacterial vac-
cines are immunogenic and confer protection from Mycobacterium tuberculosis challenge in
mice [30, 31]. Many tuberculosis vaccine candidates, in fact, are being evaluated in animal
models and human clinical trials [3, 32, 33], and, like DAR-901, have exhibited immunogenic-
ity and/or protective efficacy in animal studies.
Only SRL172 has been associated with protection from laboratory-proven human tubercu-
losis in a phase III randomized, double-blind, placebo-controlled, clinical trial [11]. DAR-901,
which was manufactured from the Master Cell Bank of SRL172 using a robust scalable method,
offers the safety and polyantigenic immunogenicity of a heat-inactivated, whole-cell product,
and thus represents a promising new tuberculosis vaccine candidate. A phase 1 trial of the
safety and immunogenicity of DAR-901 in BCG immunized adults with and without HIV
infection has been completed in the United States and a Phase 2 prevention of infection trial in
BCG-immunized adolescents initiated in Tanzania.
Supporting Information
S1 Data. The GraphPad Prism data file used to generate the figures in this manuscript.
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